Tripeptide · cell and animal evidence
What is KPV?
KPV stands for lysine, proline and valine, the three amino acids in its sequence. It is associated with melanocortin-related peptide research and is often discussed in intestinal inflammation.
How does KPV work?
Researchers have investigated uptake of KPV through PepT1, a transporter that moves small peptides into cells. The work examines inflammatory signalling in intestinal epithelial and immune-cell models. [1]
What does the research show?
A 2008 study tested KPV in cultured cells and two mouse colitis models. It reported changes in inflammatory signalling and experimental disease measures. Cultured human cells are not the same as a clinical trial in human patients. [1]
What the evidence does not establish
Colitis induced in a mouse does not reproduce every feature of inflammatory bowel disease in people. The experiment does not establish KPV as a treatment for Crohn’s disease, ulcerative colitis or nonspecific digestive symptoms.
Safety questions to discuss
FDA reports a lack of identified human exposure data for KPV drug products. That uncertainty is a reason to avoid assuming safety from a short amino-acid sequence. [3]
Frequently asked questions
What does KPV stand for?
It is the amino-acid sequence lysine–proline–valine.
Do human cells in a laboratory count as a human clinical trial?
No. Clinical trials study participants and patient outcomes, not only isolated cells.
Sources and further reading
- PepT1-mediated KPV uptake — cell and mouse colitis study, 2008
- KPV in murine inflammatory bowel disease models, 2008
- FDA: KPV safety information
These are selected sources, not a systematic review. Check publication dates, study methods and the exact substance tested. Artwork does not establish clinical benefit.